European Commission Withdraws Marketing Authorization for Rapilysin

The European Commission has announced the withdrawal of the marketing authorization for Rapilysin (reteplase), a medication used for the treatment of myocardial infarction. This decision, effective from January 26, 2024, came at the request of the marketing authorization holder, Actavis Group PTC ehf.

Originally granted authorization on August 29, 1996, Rapilysin was approved for use in cases of suspected myocardial infarction, particularly for patients exhibiting specific conditions indicative of acute myocardial infarction (AMI). Despite its long-standing presence in the market and a renewal period that lasted until 2006, the product has now fallen out of favor.

The withdrawal signifies a shift in the pharmaceutical landscape within the European Union, raising questions about the future availability of effective treatments for heart attacks, particularly as the industry faces increasing competition and market evaluation.

In the interim, healthcare providers will need to assess alternative treatment options for suspected myocardial infarction, ensuring that patient care remains uncompromised despite the removal of Rapilysin from the market.

For those seeking further information, the European Medicines Agency continues to provide updates on these changes. Full product information can still be accessed in all official EU languages.

Source: European Medicines Agency (EMA)